Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$42.76 USD
+0.93 (2.22%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $42.71 -0.05 (-0.12%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GPCR 42.76 +0.93(2.22%)
Will GPCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
IPO Round Up of First Half of 2023
Other News for GPCR
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Jefferies Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Maintained Buy Rating: Overreaction to Sell-off Undervalues Structure Therapeutics’ Market Potential
Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
Structure Therapeutics: Yet Another Potential GLP-1 Entrant